Archive
Home / Media Centre / Archive
Here you can find the archive of all Press Releases prior to 2022
Filter by date:
Showing 1107 press releases before 2022
-
AstraZeneca and Bristol-Myers Squibb resubmit dapagliflozin New Drug Application for the treatment of type 2 diabetes in the U.S
-
US FDA acknowledges receipt of resubmission of the New Drug Application for investigational compound dapagliflozin for the treatment of type 2 diabetes
-
Simon Lowth, Chief Financial Officer, to leave AstraZeneca
-
AstraZeneca collaborates with Cambridge medical research institutions to advance cancer research
-
AstraZeneca Completes Acquisition Of Pearl Therapeutics
-
AstraZeneca and Bristol-Myers Squibb announce top-line results for SAVOR-TIMI-53 cardiovascular outcomes trial of ONGLYZA® (SAXAGLIPTIN)
-
AstraZeneca selects location for new global R&D centre and corporate headquarters in Cambridge, UK
-
MedImmune, AstraZeneca’s biologics arm, and NGM Biopharmaceuticals announce agreement to discover and develop therapies for diabetes and obesity
-
AstraZeneca to acquire Pearl Therapeutics to strengthen respiratory portfolio
-
AstraZeneca announces top-line results from Phase III OSKIRA Trials of FOSTAMATINIB and decision not to proceed with regulatory filings
Latest articles and press releases
All of our latest press releases and articles are available to explore
